Lack of evidence for natural cytotoxicity deficiency against human ex vivo tumour cells in allograft recipients

Nephrology Dialysis Transplantation

Volumn 12, Issue 5, 1997, Pages 988-994

  Alamartine, E ^a,d   Sabido, O ^b   Dumollard, J M ^c   Berthoux, F ^a  

^a Grp Rech sur les G   (France)

^b Ctr Commun de Cytometrie en Flux   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

^d HÔPITAL NORD   (France)

Author keywords

Natural cytotoxicity; Natural killer cells; Transplantation; Tumour cells

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CELLULAR IMMUNODEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; KIDNEY ALLOGRAFT; LYMPHOKINE ACTIVATED KILLER CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; RECIPIENT; TUMOR CELL;

CASE-CONTROL STUDIES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNE TOLERANCE; IMMUNITY, NATURAL; KIDNEY TRANSPLANTATION; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030927663     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.5.988     Document Type: Article

References (30)

1. Penn I. Malignancy. Surg Clin North Am 1994; 74: 1247-1257
2. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngenic and allogenic tumours. Int J Cancer 1975; 16: 230-239
3. Lipinski M, Tursz T, Kreis H. Dissociation of natural killer activity and antibody-dependent cell-mediated cytotoxicity in kidney allograft recipients receiving high-dose immunosuppressive therapy. Transplantation 1980; 29: 214-218
4. Introna M, Allaverna P, Spreafico F, Mantovani A. Inhibition of human natural killer activity by cyclosporin A. Transplantation 1981; 31: 113-116
5. Moreau JF, Ythier A, Soulillou JP. Natural killer activity in kidney allograft recipients. Transplant Proc 1981; 13: 1610-1613
6. Penn I. Why do immunosuppressed patients develop cancer? Oncogenesis 1989; 1: 27-52
7. Alamartine E, Sabido O, Berthoux F. The low number of natural killer cells in renal transplant recipients with de novo malignancies. Transplantation 1992; 54: 569-571
8. Lanier LL, Le AM, Civin CI. The relationship of CD16 (leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic lymphocytes. J Immunol 1986; 136: 4480-4486
9. Yokoyama WM. Natural killer cell receptors. Curr Opin Immunol 1995; 7: 110-120
10. Herberman RB, Reynolds CW, Ortaldo JR. Mechanism of cytotoxicity by Natural Killer (NK) cells. Ann Rev Immunol 1986; 4: 651-680
11. Grimm EA, Mazunder A, Zhang HZ. Lymphokine-activated killer cell phenomenon: Lysis of NK-resistant fresh solid tumour cells. J Exp Med 1982; 155: 1823-1841
12. Klein E, Mantovani A. Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 1993; 5: 714-718
13. Whiteside TL, Herberman RB. Human Natural Killer cells in health and diseases: biological and therapeutic potential. Clin Immunother 1994; 1: 56-66
14. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995; 7: 404-410
15. + cells. Transplantation 1990; 50: 250-257
16. Alamartine E, Sabido O, Berthoux F. The influence of prophylactic immunosuppressive regimens on natural killer and lymphokine-activated killer cells in renal transplant recipients. Transplantation 1990; 50: 969-973
17. Prince HA, Ettenberg RB, Dorey FJ, Fine RN, Fahey JL. Azathioprine suppression of Natural Killer activity and antibody-dependent cellular cytotoxicity in renal transplant recipients. J Clin Immunol 1984; 4: 312-318
18. Muul LM, Gately MK. Hydrocortisone suppresses the generation of nonspecific anomalous killers but not specific cytolytic T lymphocytes in human mixed lymphocyte-tumour cultures. J Immunol 1984; 132: 1202
19. Smilie AE, Petrie JJB, Rigby RJ. Effect of immunosuppression regimen and in vitro lymphokines on natural killer activity in renal transplantation. Clin Transplant 1989; 3: 273-278
20. Kasaian MT, Biron CA. Cyclosporin A inhibition of Interleukin-2 gene expression, but not natural killer cell proliferation, after Interferon induction in vivo. J Exp Med 1990; 171: 754-762
21. Grimm EA, Muul LM, Wilson DJ. The differential inhibitory effects exerced by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukine-2 versus CTL. Transplantation 1985; 39: 537-540
22. Alamartine E, Sabido O, Berthoux F. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. Nephrol Dial Transplant 1994; 9: 1456-1461
23. McGinnes K, Chapman G, Marks R, Prenny R. A fluorescence NK assay using flow cytometry. J Immunol Methods 1986; 86: 7-15
24. Brunning JW, Kardol MJ, Naipal A. Carboxyfluorescein fluochromasia assays for cell-mediated lympholysis and ADCC: a nonradioactive technique. Transplant Proc 1979; 11: 1961-1963
25. Vujanovic NL, Herberman RB, Maghazachi AA. Lymphokine-activated killer cells in rats-III: A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into LAK. J Exp Med 1988; 167: 15-29
26. Alamartine E, Berthoux F. Tumours in kidney transplanted patients: A one-centre comprehensive study. Transplant Proc 1995; 2: 1761-1763
27. Vanky F, Klein E. Auto-tumour lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity. Cancer Immunol Immunother 1989; 29: 125-132
28. Gumperz JE, Parham P. The enigma of the natural killer cell. Nature 1995; 378: 245-248
29. Scalzo A, Fritzgerald NA, Simmons A, Lavista AB, Shellam GR. The effect of the Cmv-1 resistance gene, which is linked to natural killer cell gene complex, is mediated by natural killer cells. J Immunol 1992; 149: 581-589
30. Romagnani S. Induction of Th1 and Th2 responses: a key role for the natural immune response? Immunol Today 1992; 13: 379-381